ABSTRACT
AIM: To analyse the correlation between (18)F-FDG uptake assessed by PET/CT in locally advanced breast tumours and histopathological and immunohistochemical prognostic factors. MATERIAL AND METHODS: Thirty-six women with breast cancer were prospectively evaluated. PET/CT was requested in the initial staging previous to adjuvant chemotherapy (multicentric study). All the patients underwent an (18)F-FDG PET/CT with a dual-time-point acquisition. Both examinations were evaluated qualitatively and semiquantitatively with calculation of SUVmax values in PET-1 (SUV-1) and in PET-2 (SUV-2) and the percentage variation of the standard uptake values (retention index) between PET-1 and PET-2. Clinical and metabolic stages were assessed according to TNM classification. The biological prognostic parameters, such as the steroid receptor status, p53 and c-erbB-2 expression, proliferation rate (Ki-67), and grading were determined from tissue of the primary tumour. Metabolic and biological parameters were correlated. RESULTS: A positive relationship was found between semiquantitative metabolic parameters and biological parameters. SUV-1 and SUV-2 values did not show significant statistical correlation (p<.05) except for the clinical tumour size. About the biological parameters, retention index showed the best results with positive and significant relation (p<.05) with estrogen and progesterone receptor status and Ki-67. Isolated SUV values did not show significant relation to these parameters. CONCLUSION: Retention index showed the best relation with biological parameters compared to isolated SUVmax values. These data suggest that SUV change over time is a prognostic marker.
Subject(s)
Breast Neoplasms/diagnostic imaging , Carcinoma, Ductal, Breast/diagnostic imaging , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Multimodal Imaging , Positron-Emission Tomography , Radiopharmaceuticals , Tomography, X-Ray Computed , Adult , Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/chemistry , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/surgery , Carcinoma, Lobular/chemistry , Carcinoma, Lobular/diagnostic imaging , Carcinoma, Lobular/drug therapy , Carcinoma, Lobular/pathology , Carcinoma, Lobular/surgery , Chemotherapy, Adjuvant , Estrogens , Female , Humans , Ki-67 Antigen/analysis , Lymphatic Metastasis , Middle Aged , Neoadjuvant Therapy , Neoplasm Grading , Neoplasms, Hormone-Dependent/chemistry , Neoplasms, Hormone-Dependent/diagnostic imaging , Neoplasms, Hormone-Dependent/drug therapy , Neoplasms, Hormone-Dependent/pathology , Neoplasms, Hormone-Dependent/surgery , Progesterone , Prognosis , Prospective Studies , Receptor, ErbB-2/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Tumor BurdenABSTRACT
AIM: To evaluate the effect of the 18F-FDG PET-CT respiratory gating (4D) study in the correct documentation of pulmonary lesions with faint uptake in standard PET-CT. METHODS: Forty-two pulmonary lesions with a low or no detectable uptake of FDG (SUV(max) < 2.5) in 3D PET-CT were prospectively evaluated in 28 patients (19 males and 9 females), mean age 66.5 years (41-81). 22 patients had neoplastic background. A conventional PET-CT (3D) total body scan was performed approximately 60 min after iv injection of a mean dose of 370 MBq. Furthermore, a 4D PET-CT (synchronized with respiratory movement) thorax study was acquired. SUV(max) was determined for each lesion in both studies. For the 4D studies, we selected the SUV(max) in respiratory period with the highest uptake ("best bin"). We calculated the SUV(max) percentage difference between 3D and 4D PET-CT (% difference = SUV(max) 4D - SUV(max) 3D/SUV(max) 3D x 100) and the relation of this value with the size and locations of the lesions. In 4D study, any lesion with SUV(max) > or = 2.5 was classified as malignant. We assessed the changes of lesion classification (from benign to malignant) applying the 4D technique. The final diagnosis was obtained by histological assessment or clinical and radiological follow-up longer than 12 months. RESULTS: Forty out of 42 lesions showed an increase of SUV(max) in the 4D study with respect to 3D. The mean SUV(max) in the 3D and 4D PET-CT studies were 1.33 (+/-0.59) and 2.26 (+/-0.87), respectively. The SUV(max) percentage difference mean between both techniques was 83.3% (+/-80.81).The smaller the lesion the greater was the SUV(max) percentage difference (P < 0.05). No differences were observed depending on the location of the lesion. In 40% of cases, there was a change in the final classification of lesions from benign to malignant. In the final diagnosis, 24 lesions were malignant. 4D PET-CT diagnosed correctly the 52% of them. CONCLUSIONS: The 4D PET-CT study permitted a better characterization of malignant lung lesions compared with the standard PET-CT, because of its higher sensitivity. 4D PET-CT is a recommendable technique in the early diagnosis of malignant lesions.
